VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
LKFT
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
LKFTLakefront Biotherapeutics N.V.
$34.39$2.2B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksLKFTCash Flow

Lakefront Biotherapeutics N.V. (LKFT) Cash Flow Statement

22Y historyFree accessUpdated daily

Operating cash flow was negative $32.9M in 2026Q3 and negative $82.8M in 2026Q1, implying free cash flow margins of -4.4% and -12.8% and suggesting that buybacks of $38.1M are being funded from balance sheet resources rather than internally generated cash.

Income StatementBalance SheetCash FlowRatios

LKFT Cash Flow Statement

Annual statement

LKFT Cash Flow Statement

Lakefront Biotherapeutics N.V. (LKFT) cash flow statement — 22-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04
Cash from Operations-163.13M-257.46M---500.54M-503.83M-427.34M3.6B-142.47M-147.03M239.4M-114.59M-75.56M522K64.1M-11.99M-18.57M6.3M-8.21M371K-9.31M-3.89M-2.71M
Operating CF Margin %--23.15%---207.48%-103.91%-89.39%430.82%-49.32%-115.69%184.84%-289.64%-108.92%0.38%47.04%-12.51%-15.17%6.77%-10.66%0.56%-26.48%-34.58%-34.85%
Operating CF Growth %147.42%---0.65%-17.9%-111.88%2624.74%3.1%-161.42%308.92%-51.66%-14574.14%-99.19%634.6%35.44%-394.67%176.78%-2312.67%103.98%-139.52%-43.43%-
Net Income796.09M320.88M---217.99M-103.23M-305.44M166.42M-29.26M-115.7M54.01M-118.41M33.21M-11.02M-6.61M-32.94M1.03M1.66M-15.21M-21.87M-11.81M-6.65M-3.61M
Depreciation & Amortization3.04M55.88M--65.57M34.64M18.68M12.1M5.08M4.29M4.18M3.4M4.65M8.15M9.01M12.1M11.63M6.96M7.37M8.35M4.73M1.31M1M
Stock-Based Compensation024M--88.51M70.73M79.96M026.76M16.54M11.03M5.04M2.95M2.74M2.09M2.04M2.42M2.64M1.33M1.08M703K00
Deferred Taxes0-18.14M--2.84M2.42M2.12M050K198K235K-1.22M2.34M-2.95M1.71M-2.2M-224K1.35M6.52M-82K-4.5M00
Other Non-Cash Items-104.78M236.49M---60M-78M131.22M265.57M-11.71M26.22M-65.27M30.69M-68.69M154K-2K297K-4.74M-1.39M367K3.37M-2.56M-546K-64K
Working Capital Changes-851.89M-876.57M---379.47M-430.38M-353.88M3.15B-133.39M-78.56M235.21M-34.09M-50.02M3.44M57.91M8.71M-28.69M-4.92M-8.58M9.51M4.13M1.99M-41K
Change in Receivables086.59M--68.98M79.86M-177.16M-75.28M-76K-27.66M-12.98M-7.22M-10.11M1.07M-16.88M00000000
Change in Inventory028.85M---34.59M-21.17M-100K22.38K3K22K25K-44K-32K-39K291K942K344K1.26M502K-1.45M293K943K51K
Change in Payables00--00089.47M20M14.77M2.1M-26.73M02.34M000000000
Cash from Investing163.88M288.81M---1.25B541.24M757.29M-4.22B-15.91M-549K-7.29M-4.3M120.61M-8.96M-6.44M2.92M-20.18M-4.74M-9.86M-5.96M-2.47M-3.92M-148K
Capital Expenditures-1.88M-13.7M---27.39M-54.2M-42.52M-51.13M-13.72M-7.44M-4.79M-6.67M-2.8M-7.87M-6.84M-5.83M-4.25M-5.19M-5.7M-6.04M-4.27M-1.11M-148K
CapEx % of Revenue0.2%1.23%--11.35%11.18%8.89%6.12%4.75%5.85%3.7%16.85%4.04%5.72%5.02%6.08%3.47%5.57%7.41%9.17%12.14%9.88%1.9%
Acquisitions3.51M19.43M---115.27M28.7M003.33M7K0110K130.79M-1.15M08.71M-15.96M0-857K01.8M-2.81M0
Investments-----------------------
Other Investing7.82M40.76M---15.82M-3.66M-45.24M0-3.32M6.52M253K2.37M-7.38M65K399K44K35K443K-3.3M80K000
Cash from Financing-39.54M-3.27M---1.49M-3.88M22.04M1.5B287.88M353.36M396M271.37M4.21M55.82M4.03M633K31.16M18.52M-3.92M3.4M39.77M21.16M96K
Debt Issued (Net)-915K-3.27M---8.18M-7.19M-6.25M-5.7M-5K-65K-49K-43K-216K-308K-477K-343K-255K-497K-5.08M-2.51M-1.55M-351K-106K
Equity Issued (Net)-38.06M0--0001.5B296.19M363.92M392.12M278.7M054.8M2.74M553K000040.95M21.14M0
Dividends Paid00--0000000000000000000
Share Repurchases-38.06M0--0000000000000000000
Other Financing-558.73K0--6.7M3.31M28.29M0-8.31M-10.5M3.92M-7.29M4.43M00423K31.41M18.65M1.16M5.91M0368K202K
Net Change in Cash-105.86M23.63M---1.73B90.3M281.45M382.13M139.59M177.97M632.93M152.6M49.54M46.83M62.09M-7.84M-6.99M20.07M-21.98M-2.22M27.9M13.34M-2.76M
Free Cash Flow-165.01M-271.31M---537.49M-561.71M-518.65M3.57B-156.18M-154.47M234.61M-121.25M-78.36M-7.35M57.27M-17.82M-22.83M1.12M-13.91M-5.67M-13.58M-5M-2.86M
FCF Margin %-17.8%-24.39%---222.8%-115.85%-108.49%427.82%-54.07%-121.54%181.14%-306.49%-112.96%-5.34%42.03%-18.59%-18.65%1.2%-18.07%-8.61%-38.62%-44.47%-36.75%
FCF Growth %----4.31%-8.3%-114.52%2386.96%-1.11%-165.84%293.49%-54.74%-965.96%-112.84%421.3%21.91%-2143.51%108.03%-145.17%58.21%-171.63%-74.88%-
FCF per Share-2.51-4.12---8.18-8.58-7.9762.00-3.00-3.125.13-3.40-2.60-0.262.16-0.68-0.940.05-0.66-0.27-1.00-0.56-0.48
FCF Conversion (FCF/Net Income)-0.21x-0.80x--2.30x4.02x1.40x24.00x4.87x1.27x4.43x0.97x-2.27x-0.06x-11.21x0.36x-4.25x2.09x0.56x-0.02x0.82x0.59x0.76x
Interest Paid00--0000000000000000000
Taxes Paid00--0000000000000000000

Key Metrics

Growth RegimeMixed
ProfitabilityWeak
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Persistent operating cash burn

Earnings Disconnected From Operating Cash

According to reported quarterly figures, LKFT's operating cash flow ran negative in most recent quarters, with 2026Q1 operating cash outflow of $82.8M against net income of $14.5M, a gap that suggests reported profits are not converting to cash.

The 2026Q1 operating cash flow ratio of -5.71 against positive net income indicates that the earnings figure is not being supported by underlying cash generation. The 2025Q4 net income of $782.1M alongside operating cash outflow of $47.5M further suggests the reported profit is driven by non-cash or non-operating items rather than core business activity. Investors should monitor whether future operating cash flow turns positive, as the current pattern warrants further investigation into earnings quality.

Free Cash Flow Remains Deeply Negative

Based on reported figures, LKFT's free cash flow margin was -12.8% in 2026Q1 and -173.0% in 2025Q2, with free cash outflows of $82.9M and $112.9M respectively, showing no sustained move toward self-funding.

The free cash flow margins across the reported quarters appear volatile and predominantly negative, with the two most recent quarters showing outflows of $33.1M in 2026Q3 and $82.9M in 2026Q1. The absence of any positive free cash flow quarter in the supplied window suggests the business has not yet reached a point where operations fund its own investment. This pattern may indicate continued dependence on external capital, though the supplied data does not disclose financing sources.

Minimal Capital Intensity Relative to Burn

As reported in financial statements, LKFT's capital expenditure ran at 0.2% to 6.4% of revenue, with the largest CapEx of $4.2M in 2025Q2, indicating that cash burn is driven by operations rather than physical asset investment.

The low capital intensity implies that LKFT's cash consumption is not primarily a function of infrastructure build-out, which shifts scrutiny toward operating expenses and working capital. Given the CapEx figures are small relative to operating outflows, the capital spending profile does not explain the scale of the cash deficit. Investors may wish to examine the operating cost base and research spending as the primary cash drivers.

Working Capital Swings Dominate Quarterly Results

Based on LKFT's reported figures, working capital changes ranged from a $813.8M outflow in 2025Q4 to a $2.7M outflow in 2026Q3, indicating that balance sheet timing drives much of the quarterly cash variance.

The magnitude of the 2025Q4 working capital outflow of $813.8M, set against the $782.1M net income in the same quarter, suggests that reported earnings and cash timing are heavily misaligned. Such large swings may reflect revenue recognition timing or receivable and payable movements rather than sustainable operating performance. The pattern warrants further investigation into the components of working capital before inferring any underlying efficiency trend.

Buybacks Continue Despite Cash Outflows

According to recent reported figures, LKFT deployed $38.1M into share repurchases in 2026Q3 while operating cash flow was negative $32.9M, a pattern that appears to draw on balance sheet resources rather than internally generated cash.

Repurchasing shares while the business is burning operating cash raises a question about the funding source and the capital allocation priority. The supplied data does not disclose the cash balance or financing arrangements, so the sustainability of this deployment cannot be confirmed. Investors should monitor whether buybacks persist once cash reserves are tested by continued operating outflows.

Reported Profit Spike Obscures Recurring Cash Losses

As reported in the filings, the $782.1M net income in 2025Q4 coincided with $47.5M of operating cash outflow, suggesting the headline profit may rest on a single non-recurring item rather than a durable change in the cash profile.

If the 2025Q4 earnings spike is non-recurring, the more representative picture is the surrounding quarters, where operating cash outflows persisted without offsetting profit. The counter-argument to a Burning classification would require evidence that the spike reflects sustainable operating conversion, which the supplied cash flow figures do not show. Investors should weigh the cumulative cash burn across the ten-quarter window rather than any single quarter's reported earnings.

LKFT — Frequently Asked Questions

Quick answers to the most common questions about buying LKFT stock.

How much cash does Lakefront Biotherapeutics N.V. (LKFT) generate from operations?

Lakefront Biotherapeutics N.V. (LKFT) generated $-257.5M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Lakefront Biotherapeutics N.V.'s free cash flow?

Lakefront Biotherapeutics N.V. (LKFT) reported negative free cash flow of $271.3M in 2025, indicating capital requirements exceeded cash from operations.

What is Lakefront Biotherapeutics N.V.'s capital expenditure (CapEx)?

Lakefront Biotherapeutics N.V. (LKFT) spent $13.7M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.